凝血酶激活的纤溶抑制物在肺部疾病中的研究进展  

Research Progress of Thrombin-Activatable Fibrinolysis Inhibitor in Lung Diseases

作　　者：李俊仁 李焱[1] 任思思[1] 刘丽[2] LI Junren;LI Yan;REN Sisi;LIU Li(Department of Emergency Medicine,Tianjin Beichen Hospital,Tianjin 300400,China;Department of Respiratory and Critical Care Medicine,Tianjin First Central Hospital,Tianjin 300100,China)

机构地区：[1]天津市北辰医院急诊医学科,天津300400 [2]天津市第一中心医院呼吸与危重症医学科,天津300100

出　　处：《医学综述》2024年第17期2075-2081,共7页Medical Recapitulate

摘　　要：凝血酶激活的纤溶抑制物(TAFI)是一种血液凝块形成和纤溶过程中的重要调节因子,也是一种参与炎症调节的急性反应蛋白。TAFI在炎性应答过程和凝血、纤溶反应中起调控作用,并在肺部疾病(肺栓塞、急性肺损伤、肺癌等)发生、发展中发挥重要作用,这为凝血和纤溶瀑布之间的联系及炎症反应网络提供了重要线索。TAFI在肺部疾病中的发病机制涉及炎症反应、氧化应激以及纤维化等,但具体发病机制目前尚未明确。因此,未来深入研究TAFI在肺部疾病中的具体作用信号通路机制等具有重要的临床诊断及治疗价值,有助于改善患者预后。Thrombin-activatable fibrinolysis inhibitor(TAFI)is an important regulatory factor in the formation of blood clots and fibrinolysis process,as well as an acute response protein involved in inflammation regulation.TAFI plays a regulatory role in the inflammatory response process and coagulation and fibrinolysis reactions,and plays an important role in the occurrence and development of lung diseases(such as pulmonary embolism,acute lung injury,lung cancer etc.),providing important clues for the connection between coagulation and fibrinolysis cascades and the inflammatory response network.The pathogenesis of TAFI in lung diseases involves inflammation,oxidative stress and fibrosis,but the specific pathogenesis is not yet clear.Therefore,further research on the specific signaling pathways of TAFI in lung diseases has important clinical diagnostic and therapeutic value,which can help improve the patient prognosis.

关 键 词：肺部疾病 凝血酶激活的纤溶抑制物 凝血-纤溶 炎症反应 

分 类 号：R563[医药卫生—呼吸系统]